The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A molecular correlate to the Gleason grading system for prostate adenocarcinoma
Open accessAbstract
Adenocarcinomas of the prostate can be categorized into tumor grades based on the extent to which the cancers histologically resemble normal prostate glands. Because grades are surrogates of intrinsic tumor behavior, characterizing the molecular phenotype of grade is of potential clinical importance. To identify molecular alterations underlying prostate cancer grades, we used microdissection to obtain specific cohorts of cancer cells corresponding to the most common Gleason patterns (patterns 3, 4, and 5) from 29 radical prostatectomy samples. We paired each cancer sample with matched benign lumenal prostate epithelial cells and profiled transcript abundance levels by microarray analysis. We identified an 86-gene model capable of distinguishing low-grade (pattern 3) from high-grade (patterns 4 and 5) cancers. This model performed with 76% accuracy when applied to an independent set of 30 primary prostate carcinomas. Using tissue microarrays comprising >800 prostate samples, we confirmed a significant association between high levels of monoamine oxidase A expression and poorly differentiated cancers by immunohistochemistry. We also confirmed grade-associated levels of defender against death (DAD1) protein and HSD17β4 transcripts by immunohistochemistry and quantitative RT-PCR, respectively. The altered expression of these genes provides functional insights into grade-associated features of therapy resistance and tissue invasion. Furthermore, in identifying a profile of 86 genes that distinguish high- from low-grade carcinomas, we have generated a set of potential targets for modulating the development and progression of the lethal prostate cancer phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Epstein, J. I., Allsbrook, W. C., Amin, M. B., & Egevad, L. L. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000173646.99337.b1 · Cited by 2,763
Schuenemeyer, J. H., McCullagh, P., & Nelder, J. A. (1992) · Technometrics · doi:10.2307/1269238 · Cited by 2,667
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Gleason, D. F., Mellinger, G. T., & The Veterans Administration Cooperative Urological Research Group Members of this group areS0022534717598894-57c401330b4195dbd1713587ed540477 Lino J. Arduino Veterans Administration Center (VAC), D. M. (1974) · Journal of Urology · doi:10.1016/s0022-5347(17)59889-4 · Cited by 2,214
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Raychaudhuri, S., Stuart, J. M., & Altman, R. B. (1999) · Biocomputing 2000 · doi:10.1142/9789814447331_0043 · Cited by 762
Redox Redux: Revisiting PTPs and the Control of Cell Signaling
Tonks, N. K. (2005) · Cell · doi:10.1016/j.cell.2005.05.016 · Cited by 702
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K. H., Fishman, D., et al. (2004) · Nature Medicine · doi:10.1038/nm1125 · Cited by 509
Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
Albertsen, P. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530080042039 · Cited by 464
Expression profiling reveals hepsin overexpression in prostate cancer.
Magee, J. A., Araki, T., Patil, S., Ehrig, T., True, L. D., Humphrey, P. A., Catàlona, W. J., Watson, M. A., & Milbrandt, J. (2001) · PubMed · Cited by 393
Self-citationProstate Cancer and the Will Rogers Phenomenon
Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D. H., Sanders, M. M., & Fine, J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji248 · Cited by 382
Neuroendocrine differentiation in prostatic carcinoma
Abrahamsson, P.-A. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s · Cited by 370
Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists
Allsbrook, W. C., Mangold, K. A., Johnson, M. H., Lane, R. B., Lane, C. G., Amin, M. B., Bostwick, D. G., Humphrey, P. A., Jones, E. C., Reuter, V. E., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.21134 · Cited by 332
Sutherland, B. W., Kucab, J., Wu, J., Lee, C., Cheang, M. C. U., Yorida, E., Turbin, D., Dedhar, S., Nelson, C., Pollak, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208590 · Cited by 299
Role of stroma in carcinogenesis of the prostate
Cunha, G. R., Hayward, S. W., & Wang, Y. Z. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700902.x · Cited by 298
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Elevated expression of inhibitor of apoptosis proteins in prostate cancer.
Krajewska, M., Krajewski, S., Banares, S., Huang, X., Turner, B., Bubendorf, L., Kallioniemi, O., Shabaik, A. S., Vitiello, A., Peehl, D. M., et al. (2003) · PubMed · Cited by 275
Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., Hruban, R. H., & Goggins, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206807 · Cited by 273
Peroxiredoxins in breast carcinoma.
Karihtala, P., Mäntyniemi, A., Kang, S. W., Kinnula, V. L., & Soini, Y. (2003) · PubMed · Cited by 261
Koukourakis, M. I., Giatromanolaki, A. N., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., & Sage, E. H. (2003) · PubMed · Cited by 220
Graefen, M., Karakiewicz, P. I., Cagiannos, I., Quinn, D. I., Henshall, S. M., Grygiel, J. J., Sutherland, R. L., Stricker, P. D., Klein, E., Kupelian, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.019 · Cited by 205
YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity
Giménez‐Bonafé, P., Fedoruk, M. N., Whitmore, T. G., Akbari, M., Ralph, J. L., Ettinger, S., Gleave, M. E., & Nelson, C. C. (2004) · The Prostate · doi:10.1002/pros.20023 · Cited by 165
Peroxisomal branched chain fatty acid ?-oxidation pathway is upregulated in prostate cancer
Zha, S., Ferdinandusse, S., Hicks, J. L., Denis, S., Dunn, T. A., Wanders, R. J., Luo, J., De Marzo, A. M., & Isaacs, W. B. (2005) · The Prostate · doi:10.1002/pros.20177 · Cited by 164
Zellweger, T., Ninck, C., Mirlacher, M., Annefeld, M., Glass, A. G., Gasser, T. C., Mihatsch, M. J., Gelmann, E. P., & Bubendorf, L. (2003) · The Prostate · doi:10.1002/pros.10209 · Cited by 141
Self-citationStapleton, A. M. F., Zbell, P., Kattan, M. W., Yang, G., Wheeler, T. M., Scardino, P. T., & Thompson, T. C. (1998) · Cancer · Cited by 113
Characterization of a Novel Type of Human Microsomal 3α-Hydroxysteroid Dehydrogenase
Chetyrkin, S. V., Belyaeva, O. V., Gough, W. H., & Kedishvili, N. Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102076200 · Cited by 85
Amplification and Overexpression of Elongin C Gene Discovered in Prostate Cancer by cDNA Microarrays
Porkka, K., Saramäki, O. R., Tanner, M., & Visakorpi, T. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780457 · Cited by 68
Digital expression profiles of the prostate androgen-response program
Clegg, N., Eroglu, B., Ferguson, C., Arnold, H., Moorman, A., & Nelson, P. S. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00167-4 · Cited by 37
Pietrangeli, P. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00109-8 · Cited by 33
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells
Snezhkina, A. V., Kudryavtseva, A. V., Kardymon, O. L., Savvateeva, M. V., Melnikova, N. V., Krasnov, G. S., & Dmitriev, A. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6175804 · Cited by 934
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Self-citationChandran, U. R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., Michalopoulos, G., Becich, M., & Monzon, F. A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-64 · Cited by 495
Metadata
- Authors
- True, L., Coleman, I., Hawley, S., Huang, C.-Y., Gifford, D., Coleman, R., Beer, T. M., Gelmann, E., Datta, M., Mostaghel, E., Knudsen, B., Lange, P., Vessella, R., Lin, D., Hood, L., & Nelson, P. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-07-18
- Volume
- 103
- Issue
- 29
- Pages
- 10991-10996
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2088076795
- Cited by
- 291
- References
- 36
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.